For help on how to get the results you want, see our search tips.
474 results
-
List item
Human medicine European public assessment report (EPAR): Daurismo (updated)
Glasdegib maleate, Leukemia, Myeloid, Acute
Date of authorisation: 26/06/2020,
, 
, Revision: 1, Authorised, Last updated: 08/01/2021
-
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , 
, Revision: 8, Authorised, Last updated: 08/01/2021
-
List item
Human medicine European public assessment report (EPAR): Blitzima (updated)
rituximab, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017,, 
, Revision: 9, Authorised, Last updated: 07/01/2021
-
List item
Human medicine European public assessment report (EPAR): Livogiva (updated)
teriparatide, Osteoporosis
Date of authorisation: 27/08/2020,, , Revision: 1, Authorised, Last updated: 07/01/2021
-
List item
Human medicine European public assessment report (EPAR): Zirabev (updated)
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019,, , Revision: 7, Authorised, Last updated: 07/01/2021
-
List item
Human medicine European public assessment report (EPAR): Luxturna (updated)
voretigene neparvovec, Leber Congenital Amaurosis, Retinitis Pigmentosa
Date of authorisation: 22/11/2018,, , Revision: 3, Authorised, Last updated: 05/01/2021
-
List item
Human medicine European public assessment report (EPAR): Erelzi (updated)
etanercept, Arthritis, Psoriatic, Psoriasis, Arthritis, Juvenile Rheumatoid, Arthritis, Rheumatoid, Spondylitis, Ankylosing
Date of authorisation: 23/06/2017,, , Revision: 8, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Rinvoq (updated)
Upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019,, Revision: 2, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Ontruzant (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, , Revision: 7, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Taltz (updated)
ixekizumab, Psoriasis
Date of authorisation: 25/04/2016,, Revision: 11, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Alofisel (updated)
darvadstrocel, Rectal Fistula
Date of authorisation: 23/03/2018,, , Revision: 6, Authorised, Last updated: 04/01/2021
-
List item
Human medicine European public assessment report (EPAR): Veklury
remdesivir, Coronavirus Infections
Date of authorisation: 03/07/2020,, , Revision: 4, Authorised, Last updated: 22/12/2020
-
List item
Human medicine European public assessment report (EPAR): Hemlibra
Emicizumab, Hemophilia A
Date of authorisation: 23/02/2018,, 
, Revision: 7, Authorised, Last updated: 22/12/2020
-
List item
Human medicine European public assessment report (EPAR): Anoro Ellipta (previously Anoro)
umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 15, Authorised, Last updated: 22/12/2020
-
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,, Revision: 30, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Sixmo
Buprenorphine hydrochloride, Opioid-Related Disorders
Date of authorisation: 19/06/2019,, Revision: 2, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Rybelsus
semaglutide, Diabetes Mellitus, Type 2
Date of authorisation: 03/04/2020,, Revision: 2, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Laventair Ellipta (previously Laventair)
umeclidinium bromide, vilanterol, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 14, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Mylotarg
gemtuzumab ozogamicin, Leukemia, Myeloid, Acute
Date of authorisation: 19/04/2018,, , Revision: 7, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Quofenix
delafloxacin meglumine, Skin Diseases, Bacterial
Date of authorisation: 16/12/2019,, Revision: 2, Authorised, Last updated: 21/12/2020
-
List item
Human medicine European public assessment report (EPAR): Gilenya
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011,
, , Revision: 27, Authorised, Last updated: 18/12/2020
-
List item
Human medicine European public assessment report (EPAR): Adcetris
Brentuximab vedotin, Lymphoma, Non-Hodgkin, Hodgkin Disease
Date of authorisation: 25/10/2012,, , , Revision: 28, Authorised, Last updated: 18/12/2020
-
List item
Human medicine European public assessment report (EPAR): Biktarvy
bictegravir, emtricitabine, tenofovir alafenamide, fumarate, HIV Infections
Date of authorisation: 21/06/2018,, Revision: 10, Authorised, Last updated: 18/12/2020
-
List item
Human medicine European public assessment report (EPAR): Idacio
adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease
Date of authorisation: 02/04/2019,, , Revision: 5, Authorised, Last updated: 18/12/2020
-
List item
Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene)
Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013,, , Revision: 17, Authorised, Last updated: 18/12/2020